Year ended December 31, 2022 compared with year ended December 31, 2021
For the year ended December 31, 2022, we had a net income of $11,616,356, which consisted of an unrealized gain on change in fair value of the warrant liability of $8,841,922, interest income on investments held in the Trust Account of $4,001,686, offset partially by operating expenses of $1,227,252.
For the year ended December 31, 2021, we had a net income of $10,938,980, which consisted of an unrealized gain on change in fair value of the warrant liability of $12,255,052, interest income on Treasury securities held in the Trust Account of $84,603, change in fair value of over-allotment option liability of $325,679, offset partially by formation and operating expenses of $931,308 and transaction costs incurred in connection with the initial public offering of $795,046.
Three and nine months ended September 30, 2023 compared with three and nine months ended September 30, 2022
For the three months ended September 30, 2023, we had a net loss of $4,585,022, which consisted of operating expenses of $4,103,770, unrealized loss on change in fair value of the $1.5 Million Convertible Promissory Note of $84,126, unrealized loss on change in fair value of the Capital Contribution Note of $405,044 and unrealized loss on change in fair value of the warrant liability of $750,293, partially offset by interest income on cash and investments held in the Trust Account of $275,549 and other income attributable to derecognition of deferred underwriting fees allocated to offering costs of $482,662. For the three months ended September 30, 2022, we had a net income of $2,054,375, which consisted of an unrealized gain on change in fair value of the warrant liability of $985,712 and interest income on investments held in the Trust Account of $1,241,567, offset partially by operating expenses of $172,904.
For the nine months ended September 30, 2023, we had a net loss of $4,953,115, which consisted of operating expenses of $5,651,175, unrealized loss on excess of fair value of the Capital Contribution Note over proceeds at issuance of $1,059,720, unrealized loss on change in fair value of the $1.5 Million Convertible Promissory Note of $86,515, unrealized loss on change in fair value of the Capital Contribution Note of $426,553 and unrealized loss on change in fair value of the warrant liability of $698,007, partially offset by interest income on cash and investments held in the Trust Account of $2,486,193 and other income attributable to derecognition of deferred underwriting fees allocated to offering costs of $482,662. For the nine months ended September 30, 2022, we had a net income of $9,082,288, which consisted of an unrealized gain on change in fair value of the warrant liability of $8,195,025 and interest income on investments held in the Trust Account of $1,599,373, offset partially by operating expenses of $712,110.
Liquidity, Capital Resources and Going Concern
Following the closing of the initial public offering, the partial exercise of the over-allotment option and the sale of the private placement warrants, a total of $300 million was placed in the Trust Account. The Company incurred $17,031,183 in transaction costs, including $6.0 million of underwriting fees, $10.5 million of deferred underwriting fees and $531,183 of other offering costs in connection with the initial public offering and the sale of the private placement warrants. On August 10, 2023, J.P. Morgan waived its entitlement to the payment of $10.5 million deferred underwriting fees in connection with the initial public offering.
For the nine months ended September 30, 2023, net cash used in operating activities was $971,943. The net loss of $4,953,115 was impacted by unrealized loss on excess of fair value of the Capital Contribution Note over proceeds at issuance of $1,059,720, unrealized loss on change in fair value of the Capital Contribution Note of $426,553, unrealized loss on change in fair value of the $1.5 Million Convertible Promissory Note of $86,515, unrealized gain on change in fair value of the warrant liability of $698,007, interest income on cash and investments held in the Trust Account of $2,486,193, other income attributable to derecognition of deferred underwriting fees allocated to offering costs of $482,662 and changes in operating assets and liabilities, which provided by $4,679,232 of cash in operating activities, primarily due to the increase in accounts payable and accrued expenses. For the nine months ended September 30, 2022, net cash used in operating activities was $919,060. The net income of $9,082,288 was impacted by unrealized gain on fair value of the warrant liability of $8,195,025, interest income on investments held in the Trust Account of $1,599,373 and by changes in operating assets and liabilities, which used $206,950 of cash in operating activities.
219